Trend in Prescription Medication Utilization for Opioid Use Disorder and Alcohol Use Disorder From 2015 to 2021: A Population-wide Study in a Canadian Province.
Journal
Journal of addiction medicine
ISSN: 1935-3227
Titre abrégé: J Addict Med
Pays: Netherlands
ID NLM: 101306759
Informations de publication
Date de publication:
16 Jul 2024
16 Jul 2024
Historique:
medline:
16
7
2024
pubmed:
16
7
2024
entrez:
16
7
2024
Statut:
aheadofprint
Résumé
To examine the quarterly incidence and prevalence of medications for opioid use disorder (OUD) and alcohol use disorder (AUD) from 2015 to 2021. A retrospective population-wide observational study in Manitoba, Canada, was conducted using administrative claims data from the Manitoba Centre for Health Policy to examine the incidence and prevalence of OUD (methadone, buprenorphine-naloxone, buprenorphine) or AUD medications (naltrexone, acamprosate, disulfiram) per 10,000 individuals in each quarter between January 1, 2015, and December 31, 2021. There were 1179 and 451 individuals who received at least one prescription for OUD and AUD, respectively, in the first quarter of 2020. The prevalence of OUD medications more than doubled from 6.3 to 14.3 per 10,000 from January 1, 2015, to December 31, 2021. Likewise, AUD medication prevalence increased almost 10-fold from 0.68 to 6.5 per 10,000 from January 1, 2015, to December 31, 2021, primarily due to naltrexone. The incidence of AUD prescription use increased 8.6-fold from 0.29 to 2.51 per 10,000 during the study period. In contrast, the incidence of opioid agonist therapy declined from 2.1 per 10,000 in the first quarter of 2015 to 0.53 per 10,000 the first quarter of 2016, primarily due to methadone. Whereas methadone incidence declined, buprenorphine-naloxone incidence increased almost 15-fold during the study period. An increase in both AUD medication prevalence and incidence in addition to an increase in buprenorphine-naloxone incidence was observed. These findings reflect an increase in the uptake of medications for treating AUD and OUD following changes to improve coverage and access to these medications.
Identifiants
pubmed: 39012008
doi: 10.1097/ADM.0000000000001348
pii: 01271255-990000000-00345
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Addiction Medicine.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
National Institute on Drug Abuse (NIDA). Drug misuse and addiction. Available at: https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction/drug-misuse-addiction. Accessed October 13, 2023.
United Nations Office on Drugs and Crime (UNODC). World Drug Report 2022. United Nations Publication, 2022. Available at: www.unodc.org/unodc/en/data-and-analysis/world-drug-report-2022.html. Accessed October 13, 2023.
Castelpietra G, Knudsen AKS, Agardh EE, et al. The burden of mental disorders, substance use disorders and self-harm among young people in Europe, 1990–2019: findings from the Global Burden of Disease Study 2019. Lancet Reg Health Eur. 2022;16:100341.
Government of Manitoba. Epidemiology and Surveillance Unit. Substance Related Harms Surveillance. Last updated October 13, 2023. Available at: https://manitoba.ca/mh/srh-public-report.html. Accessed December 12, 2023.
Canadian Centre on Substance Use and Addiction. Alcohol (Canadian Drug Summary). 2019. Available at: https://www.ccsa.ca/alcohol-canadian-drug-summary. Accessed December 12, 2023.
Canadian Centre on Substance Use and Addiction. Opioids (Canadian Drug Summary). 2022. Available at: https://www.ccsa.ca/opioids-canadian-drug-summary. Accessed December 12, 2023.
Canadian Centre on Substance Use and Addiction. Canada’s Guidance on Alcohol and Health: Final Report. 2023. Available at: https://www.ccsa.ca/canadas-guidance-alcohol-and-health. Accessed December 12, 2023.
Canadian Substance Use Costs and Harms (CSUCH). Data Visualization Tool. Available at: https://csuch.ca/explore-the-data/. Accessed November 30, 2023.
Leong C, Bolton JM, Ekuma O, et al. Association of alcohol use disorder on alcohol-related cancers, diabetes, ischemic heart disease and death: a population-based matched cohort study. Addiction. 2022;117(2):368–381.
Bolton JM, Leong C, Ekuma O, et al. Health service use among Manitobans with alcohol use disorder: a population-based matched cohort study. CMAJ Open. 2020;8(4):E762–E771.
Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings. JAMA. 2014;311(18):1889.
Santo T Jr., Clark B, Hickman M, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiatry. 2021;78(9):979–993.
Konrad G, Leong C, Bolton JM, et al. Use of pharmacotherapy for alcohol use disorder in Manitoba, Canada: a whole-population cohort study. PLoS One. 2021;16(9):e0257025.
Spithoff S, Turner S, Gomes T, et al. First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario. Can Fam Physician. 2017 May;63(5):e277–e283.
Socias ME, Dong H, Wood E, et al. Trajectories of retention in opioid agonist therapy in a Canadian setting. Int J Drug Policy. 2020;77:102696.
Province of Manitoba: news release: changes to provincial formulary making it easier to access addictions medications. (2019). Available at: https://news.gov.mb.ca/news/index.html?archive=&item=45176. Accessed October 30, 2023.
Province of Manitoba: bulletin 108: Manitoba drug benefits and interchangeability formulary amendments. (2020). Available at: https://www.gov.mb.ca/health/mdbif/bulletin108.pdf. Accessed October 30, 2023.
The College of Physicians and Surgeons of Manitoba. Manitoba Opioid Agonist Therapy Recommended Practice Manual. 1.5 The relationship with pharmacy and prescriptions for opioid agonist therapy. (2023). Available at: https://cpsm.mb.ca/assets/PrescribingPracticesProgram/Relationship%20with%20Pharmacy%20&%20Prescriptions%20for%20OAT.pdf?utm_source=web&utm_medium=direct&utm_campaign=OATmanual. Accessed October 30, 2023.
Manitoba Government Press Release. First rapid access to addictions medicine clinic opens in Winnipeg. (2018). Available at: https://news.gov.mb.ca/news/index.html?archive=&item=44582. Accessed October 30, 2023.
eCPS. Methadose™ Product Monograph. Last updated February 25, 2019. Available at: https://www-e-therapeutics-ca.uml.idm.oclc.org/. Accessed December 12, 2023.
eCPS. Suboxone® Product Monograph. Last updated October 26, 2021. Available at: https://www-e-therapeutics-ca.uml.idm.oclc.org. Accessed December 12, 2023.
Province of Manitoba: bulletin 91: Manitoba drug benefits and interchangeability formulary amendments. (2017). Available at: http://www.gov.mb.ca/health/mdbif/bulletin91.pdf. Accessed October 30, 2023.
Lefebvre LG. Alcohol-related disorders. Last updated April 28, 2021. Available at: https://www-e-therapeutics-ca.uml.idm.oclc.org. Accessed December 12, 2023.
eCPS. Campral® Product Monograph. Last updated January 23, 2019. Available at: https://www-e-therapeutics-ca.uml.idm.oclc.org. Accessed December 12, 2023.
Drug Shortages Canada. Drug Shortage Report Campral. (2020. Available at: https://www.drugshortagescanada.ca/shortage/72306. Accessed December 12, 2023.
Samji H, et al; for the British Columbia Centre for Disease Control COVID-19 Young Adult Task Force. Impacts of the COVID-19 Pandemic on the Health and Well-being of Young Adults in British Columbia. British Columbia Centre for Disease Control, 2021. Available at: http://www.bccdc.ca/Health-Professionals-Site/Documents/COVID-Impacts/BCCDC_COVID-19_Young_Adult_Health_Well-being_Report.pdf Accessed October 30, 2023.
McDonald R, Bech AB, Clausen T. Flexible delivery of opioid agonist treatment during COVID-19 in Norway: qualitative and quantitative findings from an online survey of provider experiences. BMC Health Serv Res. 2023;23:965.
Adams A, Blawatt S, Magel T, et al. The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic review. Subst Abuse Treat Prev Policy. 2023;18:56.
Kitchen SA, Campbell TJ, Men S, et al. Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: a population-based time-series analysis. Int J Drug Policy. 2022;103:103644.
Scherrer JF, Sullivan MD, LaRochelle MR, et al. Validating opioid use disorder diagnoses in administrative data: a commentary on existing evidence and future directions. Addict Sci Clin Pract. 2023;18:49.
Wansrisuthon W, Ratta-apha W, Thongchot L, et al. Accuracy of diagnosis and International Classification of Diseases; Tenth Revision coding for alcohol dependence, alcohol withdrawal, and alcohol-withdrawal delirium among inpatients at a university hospital. J Addict Med. 2017;11(3):241–242.